EVEvaxion Biotech A/S EVAX · NASDAQ
$2.75 -8.33% (-$0.25)
- Market cap
- $17.4M
- Enterprise value
- $10.5M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 2.3x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -46.7%
- Gross margin
- 100.0%
- Net margin
- -115.5%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.27
- Free float
- 80.8%
About the company
Evaxion Biotech A/S (EVAX) is a biotechnology company specializing in the development of immunotherapeutic treatment approaches in oncology and infectious diseases. The company focuses on developing personalized vaccines and treatment methods based on the analysis of patients' immune responses. Evaxion Biotech aims to innovate in diagnostics and therapy to enhance a patient's ability to fight against cancer and infections. Their approaches are based on utilizing modern technologies and data analytics. Shares of Evaxion Biotech A/S (EVAX) can be an interesting choice for investors tracking the biotechnology sector and innovations in the field of immunotherapy.
Sector
Healthcare
Industry
Biotechnology
CEO
Helen Katrina Tayton-Martin
Employees
46
Headquarters
Horsholm
Valuation
Is today's price reasonable?
- What speaks for it: The share price is below the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What to watch: It missed profit estimates 5 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $14.0M against $7.10M.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number